Assessing the Benefits of Drug Delivery by Nanocarriers: A Partico/Pharmacokinetic Framework
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: An in vivo kinetic framework is introduced to analyze and predict the quantitative advantage of using nanocarriers to deliver drugs, especially anticancer agents, compared to administering the same drugs in their free form. METHODS: This framework recognizes three levels of kinetics. First is the particokinetics associated with deposition of nanocarriers into tissues associated with drug effect and toxicity, their residence inside those tissues, and elimination of the nanocarriers from the body. Second is the release pattern in time of free drug from the nanocarriers. Third is the pharmacokinetics of free drug, as it relates to deposition and elimination processes in the target and toxicity associated tissues, and total body clearance. A figure of merit, the drug targeting index (DTI), is used to quantitate the benefit of nanocarrier-based drug delivery by considering the effects of preferential deposition of nanoparticles into target tissues and relative avoidance of tissues associated with drug toxicity, compared to drug that is administered in its free form. RESULTS: General methods are derived for calculating DTI when appropriate particokinetic, pharmacokinetic, and drug release rate information is available, and it is shown that relatively simple algebraic forms result when some common assumptions are made. CONCLUSION: This approach may find use in developing and selecting nanocarrier formulations, either for populations or for individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This metric reduces the time-concentration data to a single average value, neglects overall exposure time and does not relate the tumor and systemic exposure [242, 243].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [242]
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 2×
“Indeed, the absence of significant lymphatic drainage is considered to be the mechanism of retention of nanocarriers in tumors, which is part of the EPR effect [3], [4].”
BackgroundAnalysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · cited 1×
“Elimination of nanocarriers occurs by renal filtration when the carriers are sufficiently small [53], by biliary secretion, or by opsonization followed by recognition, uptake and destruction by macrophages (e.”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Self-citationNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
“This metric reduces the timeconcentration data to a single average value, neglects overall exposure time and does not relate the tumor and systemic exposure [242,243].”
BackgroundNanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520
Self-citationAdvanced drug delivery and therapeutic strategies for tuberculosis treatment
Nair, A., Greeny, A., Nandan, A., Sah, R. K., Jose, A., Dyawanapelly, S., Junnuthula, V., Athira, K. V., & Sadanandan, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02156-y · Cited by 121
Advances in atom-transfer radical polymerization for drug delivery applications
Rodrigues, P. R., & Vieira, R. P. (2019) · European Polymer Journal · doi:10.1016/j.eurpolymj.2019.03.023 · Cited by 62
Genotype-targeted local therapy of glioma
Shankar, G. M., Kirtane, A. R., Miller, J. J., Mazdiyasni, H., Rogner, J., Tai, T., Williams, E. A., Higuchi, F., Juratli, T. A., Tateishi, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805751115 · Cited by 55
Self-citation
Metadata
- Authors
- Siegel, R. A., Kirtane, A. R., & Panyam, J.
- Affiliations
- University of Minnesota (US)
- Venue
- IEEE Transactions on Biomedical Engineering
- Published
- 2017-09
- Volume
- 64
- Issue
- 9
- Pages
- 2176-2185
- ISSN
- 0018-9294 (ISSN-L)
- 1558-2531
- OpenAlex
- W2558264310
- Cited by
- 14
- References
- 57
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 1
- FWCI
- 0.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- IEEE Transactions on Biomedical Engineering (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Doctoral Dissertation Fellowship from the University of Minnesota
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- nanocarriers, drug delivery, pharmacokinetics, anticancer agents, drug release kinetics, drug toxicity, personalized drug delivery
- MeSH terms
- Animals, Antineoplastic Agents, Biological Availability, Computer Simulation, Diffusion, Drug Evaluation, Preclinical, Humans, Models, Biological, Models, Chemical, Neoplasms, Drug Design, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.